Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Docetaxel, IV Cisplatin, and Oral TS-ONE in Gastric Cancer with Peritoneal Carcinomatosis
NCT02024841Phase 1Completed
- Sponsor
- The University of Hong Kong
- Start
- Dec 2013
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docetaxel in gastric cancer (GC) and peritoneal carcinomatosis (PC), sponsored by The University of Hong Kong. Primary endpoint: Maximum tolerated dose and recommended dose at 2 years. Started Dec 2013; status: completed.
02
Drugs
docetaxel
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT02024841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02024841.